The ideal state of neuroradiology according to Dr. Kevin Berger? More objective data and more integrations in software-driven imaging quantification

We recently spoke with Kevin Berger, MD, from Chesapeake Medical Imaging about his history in neuroradiology, how he’s seen imaging quantification progress over the years, and the benefits he sees from tools such as cMRI.

Continue ReadingThe ideal state of neuroradiology according to Dr. Kevin Berger? More objective data and more integrations in software-driven imaging quantification

Imaging biomarkers play a crucial role in the development, approval, and use of disease-modifying drugs for Alzheimer’s disease

Biomarkers, including imaging biomarkers, will be important for managing patients with Alzheimer's disease on disease-modifying drugs (DMD), such as Aduhelm and Leqembi, across the patient pathway.

Continue ReadingImaging biomarkers play a crucial role in the development, approval, and use of disease-modifying drugs for Alzheimer’s disease

In radiology, AI has moved from a buzzword to a valuable tool: RSNA 2022

AI in radiology is here to stay. The next challenge is ensuring it’s seamlessly integrated into radiologists’ and technicians’ imaging workflows. Read about these and other takeaways from RSNA 2022 in this blog post from Richard Hausmann, CEO; Lennart Thurfjell, COO; and Greg Kingston, CMO.

Continue ReadingIn radiology, AI has moved from a buzzword to a valuable tool: RSNA 2022

Earlier diagnosis is essential for better dementia care: conversations at AAIC 2022

For the collective dementia community, an earlier diagnosis leads to more appropriate care and, ultimately, better patient outcomes. Read more about how thought leaders and clinicians at AAIC 2022 suggest we can improve dementia diagnosis in this blog post.

Continue ReadingEarlier diagnosis is essential for better dementia care: conversations at AAIC 2022

Building trust in AI for routine radiology use: what we heard at ECR 2022

The need to demystify AI in radiology applications was one of our key takeaways from ECR 2022. Read about some of the discussions and other themes in this blog post from Peter Ngum, Combinostics Clinical Application Specialist, and Greg Kingston, Combinostics Chief Marketing Officer (CMO).

Continue ReadingBuilding trust in AI for routine radiology use: what we heard at ECR 2022

Slicing through the fog of neurodegeneration with cutting-edge tools: feedback from ASNR22

ASNR22 provided a great opportunity to discuss tools that would help neuroradiologists support their referring clinicians when diagnosing patients with symptoms of dementia. Read key takeaways from Peter Ngum, Combinostics Clinical Application Specialist, and Greg Kingston, Combinostics Chief Marketing Officer (CMO).

Continue ReadingSlicing through the fog of neurodegeneration with cutting-edge tools: feedback from ASNR22

Preserving the mind: key takeaways from AAN 2022

AAN 2022 highlighted cutting-edge research in neurology and provided opportunities for networking within the neurology community. Read key takeaways from Peter Ngum, Combinostics Clinical Application Specialist, from advances for traumatic brain injury to the future of AI and neurology.

Continue ReadingPreserving the mind: key takeaways from AAN 2022

The future of MS biomarkers: key takeaways from ACTRIMS 2022

ACTRIMS 2022 highlighted novel scientific discoveries for multiple sclerosis (MS), with a focus on MS biomarkers. Read key takeaways from Peter Ngum, Combinostics Clinical Application Specialist, from better, novel treatments to the potential of enhanced AI-based neuroimaging for improved patient management.

Continue ReadingThe future of MS biomarkers: key takeaways from ACTRIMS 2022